Health
Australian Government Grants TB Alliance an Award to Help Bolster Clinical Research and Improve Access to New Treatments for Drug-Resistant TB
AUD 17 Million Grant over 5 Years Will Fund Next-Generation TB Cures CANBERRA, Australia, March 25, 2024 /PRNewswire/ -- The Australian Government, through the Partnerships for a Healthy Region initiative, has announced a new AUD 17 million grant to support work with TB Alliance through its Pro...
2024-03-25 08:04
1069
Veeva Vault EDC Surpasses 1,000 Study Start Milestone
Eight of the top 20 biopharmas standardize on Vault EDC to build a modern
clinical data foundation
SINGAPORE, March 25, 2024 /PRNewswire/ -- Veeva Systems
2024-03-25 08:00
1989
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding it...
2024-03-22 19:00
4016
Duyun Maojian tea forest enters spring harvest season in China's Guizhou
DUYUN, China, March 22, 2024 /PRNewswire/ -- Duyun Maojian tea leaves mainly grow in Duyun City, Bouyei-Miao Autonomous Prefecture of Qiannan, southwest China's Guizhou Province. In history, they were used as a tribute to the imperial court and given the name "fish hook tea" since dried tea leaves...
2024-03-22 18:59
3247
The Results of Phase II Clinical Study of KN046 Plus Chemotherapy as First-line Treatment for Metastatic NSCLC were Published in Cell Reports Medicine
SUZHOU, China, March 22, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical research results of anti- PD-L1/CTLA-4 bispecific antibody KN046 plus chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC) were published o...
2024-03-22 18:42
2821
Frost & Sullivan Launches the 2024 Edition of India Manufacturing Excellence and Sustainability 4.0 Awards
~Nominations are open until March 31, 2023~ ~Award ceremony to be held on December 13, 2024~ MUMBAI, India, March 22, 2024 /PRNewswire/ -- Frost & Sullivan proudly announces the launch of its prestigious awards ceremonies- the15th edition of the Sustainability 4.0 Awardsand the 20th edition of th...
2024-03-22 18:30
2057
Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline
* Promising clinical activities and efficacies during dose escalations for four lead global rights programs targeting CD24, Claudin 18.2, CD73, and PD-L1/4-1BB * Positive, differentiated cervical cancer data advancing mTORC1/2 inhibitor on registrational track for APAC markets * RMB1.188 bi...
2024-03-22 18:00
6267
Lynk Pharmaceuticals Announces First Atopic Dermatitis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001
BOSTON and HANGZHOU and SHANGHAI, China, March 22, 2024 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, announced that it has dosed the first patient with Atopic Dermatitis (AD) in a Phase Ⅲ ...
2024-03-22 08:00
2525
NeuExcell Therapeutics Announces Successful Dosing of First Patient by NeuroD1 Gene Therapy
SUZHOU, China, March 22, 2024 /PRNewswire/ -- NeuExcell Therapeutics, a leading biotechnology company focused onin vivo neural regenerative therapies, announces the successful dosing of the first patient with the first-in-class NeuroD1 gene therapy product NXL-004. This milestone represents si...
2024-03-22 08:00
2274
OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth
SHANGHAI, March 21, 2024 /PRNewswire/ -- On the evening of March 21st, OcuMension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "OcuMension" or the "Company") disclosed its 2023 annual performance report. The company achieved a total operating income ofRMB 246.4 million ...
2024-03-21 22:44
3722
Ping An Reports RMB117,989 million of Operating Profit Attributable to Shareholders of the Parent Company in 2023, cash dividend increased for 12 consecutive years
Life Insurance Rebounded with Life & Health NBV Growing 36.2% HONG KONG and SHANGHAI, March 21, 2024 /PRNewswire/ -- Ping An Insurance (Group) Company ofChina, Ltd. (hereafter "Ping An", the "Company" or the "Group", HKEX: 2318; SSE: 601318) today announced its financial results for the year end...
2024-03-21 21:10
4463
Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved
SHANGHAI, March 21, 2024 /PRNewswire/ -- Henlius (2696.HK) announced its 2023 annual results. During the reporting period, Henlius' revenue reached about RMB5.3949 billion, representing an increase of 67.8% YoY, and recorded a net profit ofRMB546.0 million. This is the first time for Henlius to a...
2024-03-21 19:47
3698
More Middle-Aged and Older Men Are Seeking Male Breast Reduction In Singapore, says Dr Ivan Puah
The mean age of men seeking gynecomastia surgery at Amaris B. Clinic Singapore was 33. However, recent years have witnessed a notable increase in older male patients above 42, with the oldest being 70. SINGAPORE, March 21, 2024 /PRNewswire/ -- Dr Ivan Puah, a Singapore MOH-accredited liposuctio...
2024-03-21 18:08
1869
Clarivate Acquires AI Start Up to Accelerate Strategy and Business Development Success for Life Sciences & Healthcare Clients
Acquisition of MotionHall reinforces strategy to lead market-specific solutions, including workflows and expert services fuelled by industry vertical AI LONDON, March 21, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, has announced an agr...
2024-03-21 16:00
2816
SK bioscience Exports Influenza Vaccine to Thailand, Entering Southern Hemisphere Market
* Company exported 440,000 doses to Thailand, marking its entry into the Southeast Asian market and the Southern Hemisphere market. * Company has obtained marketing authorizations in 12 countries, with additional approvals underway in 10 countries to expand its market worldwide. BANGKOK and S...
2024-03-21 13:24
2076
SINGAPORE'S "HUSTLE CULTURE" TAKES ITS TOLL: THE AIR STATION AND RESMED LAUNCH INITIATIVE TO ADDRESS WORK-INDUCED SLEEP ISSUES
* Global survey reveals that 39% of Singaporeans grapple with sleep, impacting health and productivity. * The Air Station and ResMed's upcoming joint initiative, "Discover Your Sleep Superpowers," aims to empower Singaporeans with free sleep screenings, complimentary sleep consultations with ...
2024-03-21 09:35
1923
TreeFrog's Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at The 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM)
- TreeFrog Therapeutics demonstrates fast, sustained, full motor recovery in preclinical models for Parkinson's Disease cell therapy program using C-Stem™ proprietary technology[1] - BORDEAUX, France, March 21, 2024 /PRNewswire/ -- TreeFrog Therapeutics, a cell therapy development company with...
2024-03-21 07:30
1883
Jiangsu Recbio Technology Co., Ltd. announced 2023 annual results report and latest progress
TAIZHOU, China, March 21, 2024 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announced its latest progress and annual results for 2023. The company always adhered to the mission of " Protect Human Health With Best-In-Class Vaccines", and achieved the following milestones and progre...
2024-03-21 00:22
3384
Sisram Medical Announces 2023 Annual Results
Revenues of US$359.3M, with the direct sales portion reaching a record high HONG KONG, March 20, 2024 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness group, featuring a dist...
2024-03-20 21:53
3729
Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study
* ATN-031 (also known as ATG-031), is the first anti-CD24 antibody to advance to the clinic in oncology inthe United States * The Phase I PERFORM trial, ongoing at four major U.S. cancer centers, is evaluating the safety and preliminary efficacy of ATN-031 in patients with advanced solid tumor...
2024-03-20 20:30
2480
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7433
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
6834
